Added to YB: 2026-09-09
Pitch date: 2026-09-06
NVO [bullish]
Novo Nordisk A/S
-0.92%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.3T
Pitch Price
DKK 45.58
Price Target
N/A
Dividend
3.91%
EV/EBITDA
8.08
P/E
11.41
EV/Sales
4.30
Sector
Pharmaceuticals
Category
turnaround
Top 5 European Stocks, September 2026: My Highest-Conviction Picks - Novo Nordisk, a bet on the healthcare sector turning
NVO (added to position): Novo Nordisk trades around DKK 292, more than 70% below its 2024 peak, and the case is being doubled down on as improving healthcare-sector results suggest investor perception may be turning despite unchanged company fundamentals. Novo raised 2026 guidance and trades at 11-12x operating cash flow, but pipeline disappointments, continued U.S. share losses to Eli Lilly and uncertainty over oral Wegovy’s realized price remain unresolved.
Read full article (2 min)